Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Epha3 Car T Cells Are Effective Against Glioblastoma In Preclinical Models

EphA3 CAR T cells are effective against glioblastoma in preclinical models

Paulo Martins1,2, Rochelle C J D'Souza3, Niclas Skarne3

  • 1QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia paulo.martins@qimrberghofer.edu.au rajiv.khanna@qimr.edu.au.

Journal for Immunotherapy of Cancer
|August 7, 2024

Related Experiment Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.7K

View abstract on PubMed

Summary
This summary is machine-generated.

Chimeric antigen receptor (CAR) T-cell therapy targeting Ephrin receptor A3 (EphA3) shows promise for glioblastoma treatment. This novel therapy effectively targets brain cancer stem cells and tumor vasculature, offering a potential new strategy for this aggressive brain cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Biology

Background:

  • Adoptive T-cell therapy is a promising strategy for glioblastoma (GBM), an aggressive brain cancer.
  • Ephrin receptor A3 (EphA3) is highly expressed in GBM, particularly on tumor vasculature and cancer stem cells, making it an ideal therapeutic target.

Purpose of the Study:

  • To design and evaluate the therapeutic potential of an EphA3-targeted chimeric antigen receptor (CAR) T-cell therapy for glioblastoma.

Main Methods:

  • Developed an EphA3-targeted CAR using a novel monoclonal antibody's single chain variable fragment.
  • Assessed CAR T-cell efficacy against patient-derived glioblastoma neurospheres, organoids, and xenografts in immunodeficient mice.

Main Results:

  • EphA3 CAR T cells efficiently recognized and killed EphA3-positive glioblastoma cells in vitro.
Keywords:
Adoptive cell therapy - ACTChimeric antigen receptor - CART cell

Related Experiment Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.7K
  • Demonstrated curative efficacy in an orthotopic xenograft glioblastoma model.
  • Showed effectiveness in targeting patient-derived glioblastoma neurospheres and organoids, inducing infiltration, disaggregation, and apoptosis.

    • Conclusions:

    • EphA3 CAR T-cell therapy holds significant therapeutic potential for glioblastoma by targeting EphA3 on cancer stem cells and tumor vasculature.
    • The therapy's effectiveness against patient-derived glioblastoma highlights its translational significance for developing targeted glioblastoma treatments.